ライフサイエンスコーパス: arterial phase

1 at enhanced homogeneously during the hepatic arterial phase.

2 etector abdominal CT during the late hepatic arterial phase.

3 28 endoleaks were also visualized during the arterial phase.

4 marrow contrast material enhancement in the arterial phase.

5 ing was also rated for the each of the three arterial phases.

6 es was superior to that of those obtained in arterial phase (0.63 [19 of 30]) (P < or =.008).

7 ined in the hepatic phase (35 HU) and in the arterial phase (25 HU).

8 sent in at least one vessel on 23 of the 105 arterial phase 3D studies.

9 High-quality arterial phase 3D volumetric interpolated breath-hold im

10 of iodinated contrast medium focused on the arterial phase, 64-detector CT angiography allowed satis

11 ic magnetic resonance imaging in the hepatic arterial phase, a timing examination was performed after

12 Use of single-breath-hold multiple arterial phase acquisition in abdominal MR imaging with

13 diagnosis of endoleaks when combined with an arterial phase acquisition.

14 minations included single-breath-hold triple arterial phase acquisition.

15 Arterial phase acquisitions were obtained during suspend

16 The number of tumors detected on arterial phase and portal venous phase images and unenha

17 Acquisition of multiple dynamic arterial phase and portal venous phase images increased

18 Arterial phase and portal venous phase pelvic CT angiogr

19 Cortical volume was calculated from arterial phase and total volume from delayed phase.

20 reviewed in the following combinations: (a) arterial phase and unenhanced scans (uniphasic/unenhance

21 Initial nonenhanced CT was followed by arterial phase and venous phase acquisitions.

22 The CC has minimal or no enhancement on arterial phase and venous phase images but intense enhan

23 cal features of HCC (hypervascularity in the arterial phase and washout in the venous phase) at contr

24 80-kVp acquisition (P < .03) than during the arterial phase and weighted-average venous phase acquisi

25 Dynamic (arterial phase) and steady-state (arterial-venous phase)

26 rpolated breath-hold imaging before, during (arterial phase), and after injection, with thin (2-mm so

27 rt), and SI(del) are tumor SI on unenhanced, arterial phase, and delayed phase three-dimensional T1-w

28 - standard deviation) of 39 HU +/- 13 in the arterial phase, and type B lesions had a difference of -

29 erent radiologist by using true nonenhanced, arterial phase, and venous phase data.

30 t-enhanced, multi-detector row CT during the arterial phase (AP), pancreatic parenchymal phase (PPP),

31 the degree of bowel wall enhancement in the arterial phase at contrast-enhanced MR imaging and (b) p

32 and change in bowel wall enhancement in the arterial phase at contrast-enhanced MR imaging over time

33 c resonance angiography during the pulmonary arterial phase at the time of an intravenous bolus of ga

34 In 80% (35 of 44) of subjects, arterial phase breath holds were shorter after gadoxetat

35 Results Arterial phase breath holds were shorter after gadoxetat

36 Arterial phase breath-holding duration and motion artifa

37 bo-controlled trial, whether maximal hepatic arterial phase breath-holding duration is affected by ga

38 Conclusion Maximal hepatic arterial phase breath-holding duration is reduced after

39 Arterial phase breath-holding duration was timed after e

40 igher in attenuation than the thyroid in the arterial phase but were lower in attenuation than the th

41 Unenhanced and arterial phase computed tomographic (CT) images were acq

42 Baseline arterial phase contrast material-enhanced (CE) MR imagin

43 The authors retrospectively reviewed 186 arterial phase contrast material-enhanced spiral CT scan

44 The authors reviewed arterial phase CT images in 100 consecutive patients wit

45 In 20 (80%) of 25 cases with hepatic arterial phase CT images, all tumors were heterogeneous

46 y be a useful tool for the interpretation of arterial phase CT studies.

47 For parenchymal injury, arterial phase CT was less sensitive (76% [68 of 90] vs

48 At arterial phase CT, enhancement similar to aortic enhance

49 Spectral imaging was used for arterial phase CT.

50 re were significantly more severely degraded arterial phase data sets for gadoxetate disodium than fo

51 between VAS score and MR imaging bowel wall arterial phase enhancement after contrast material admin

52 nal intensity on T1-weighted images, intense arterial phase enhancement after gadolinium injection, a

53 Hepatic arterial phase enhancement of cirrhotic nodules at CT an

54 -two percent of the 100 lesions demonstrated arterial phase enhancement.

55 Arterial-phase examinations (defined as relative liver e

56 he central k-space views acquired during the arterial phase for the more proximal stations.

57 At arterial phase gadolinium-enhanced magnetic resonance (M

58 contrast-enhanced MR imaging in the hepatic arterial phase (HAP) and portal venous phase (PVP).

59 l renal masses relative to the cortex in the arterial phase has 100% specificity (95% CI: 84, 100) fo

60 A retrospective review of arterial phase helical computed tomographic (CT) studies

61 Arterial phase helical CT (3-mm collimation, 1-mm recons

62 all pancreatic arteries can be delineated on arterial phase helical CT scans by using optimized techn

63 Two radiologists reviewed 100 consecutive arterial phase helical CT scans of the pancreas in patie

64 Exclusion of rim arterial phase hyperenhancement as a means of satisfying

65 he algorithmic role of tumor in vein and rim arterial phase hyperenhancement improves the diagnostic

66 ICC was 0.87 (95% CI: 0.84, 0.90) for arterial phase hyperenhancement, 0.85 (95% CI: 0.81, 0.8

67 Among masses with arterial phase hyperenhancement, the rim pattern was mor

68 Arterial phase images (1.25-mm collimation, 7.5 mm/ 0.8-

69 ase images, portal venous phase plus hepatic arterial phase images (helical biphasic CT), and CTAP pl

70 The arterial phase images also depicted no endoleaks at thes

71 Hepatic arterial phase images and CTAP images, respectively, dep

72 The arterial phase images depicted no additional endoleaks.

73 atic arteries were evaluated on the basis of arterial phase images interpreted by two independent rea

74 Eighty-three percent of arterial phase images obtained with automated contrast m

75 Subsequently, arterial phase images were analyzed.

76 sions were seen on CT studies: 48 on hepatic arterial phase images, 49 on portal venous phase phase i

77 al venous phase images, 82 tumors on hepatic arterial phase images, 87 tumors on CTAP images, 87 tumo

78 nenhanced T2-weighted SE images, 92 (84%) on arterial phase images, and 76 (69%) on portal venous pha

79 etal enhancement, marked hyperattenuation on arterial phase images, lymphadenopathy, heterogeneity, e

80 ive review, eight HCCs were detected on only arterial phase images, one on only portal venous phase i

81 mages; 10 were graded as more conspicuous on arterial phase images.

82 on nonenhanced images, and six were seen on arterial phase images.

83 ble at retrospective evaluation, but only on arterial phase images.

84 tient; range, two to 14) with unenhanced and arterial -phase imaging performed between September 2004

85 Arterial phase imaging contributed to a mean of 36.5% of

86 Study results indicate that arterial phase imaging may not be necessary for the rout

87 The addition of hepatic arterial phase imaging to portal venous phase imaging (h

88 For active bleeding, arterial phase imaging was less sensitive (70% [21 of 30

89 For intrasplenic pseudoaneurysm, arterial phase imaging was more sensitive (70% [21 of 30

90 Arterial phase imaging was noncontributory in 22 of 23 c

91 fidence intervals as indicators of how often arterial phase imaging would contribute to the diagnosis

92 examinations, there was 95% confidence that arterial phase imaging would depict an endoleak missed a

93 ntrast-enhanced liver imaging in which early arterial-phase imaging is best for detecting hepatocellu

94 s in 34, heterogeneously hyperattenuating at arterial phase in 38, and hypoattenuating at portal phas

95 Mean motion scores in all three arterial phases in the gadoxetate disodium cohort were s

96 For CT evaluation of blunt splenic injury, arterial phase is superior to portal venous phase imagin

97 Routine acquisition of images in the arterial phase is unnecessary for detection of pancreati

98 The CER of FNH in the arterial phase (mean, 94.3%+/-33.2) was significantly hi

99 Three (7%) of 44 volunteers had severe arterial phase motion artifacts after gadoxetate disodiu

100 SM transient severe motion , based on severe arterial phase motion, despite minimal motion in the oth

101 Renal arterial phase MR angiograms depicted 30 of 31 (97%) sur

102 yspnea that can have a deleterious effect on arterial phase MR image quality and occurs significantly

103 c tumor tissue on contrast material-enhanced arterial phase MR images and the amount of diffusion-res

104 Optimal hepatic arterial phase MR images can be obtained routinely with

105 Arterial phase MR images were assessed quantitatively an

106 igher in attenuation than the thyroid in the arterial phase nor lower in attenuation than the thyroid

107 Reduction in tumor enhancement in the arterial phase occurred immediately after TACE, with a c

108 col B)-were compared during the late hepatic arterial phase of contrast enhancement.

109 cquired sequentially during the late hepatic arterial phase of contrast enhancement.

110 ases a hypervascular appearance in the early arterial phase of contrast-enhancement, with a dynamic e

111 CT angiography, tMIP CT angiography, and the arterial phase of dynamic CT angiography at a vascular c

112 Image quality of the arterial phase of dynamic CT angiography was rated infer

113 ed with standard helical CT angiography, the arterial phase of dynamic CT angiography, and nonfiltere

114 The appearance of hepatic lesions in the arterial phase of enhancement has potential use in the d

115 The arterial phase of image acquisition improves detection o

116 e vascular lesion was visualized only at the arterial phase of image acquisition; the other nine cont

117 f dual-energy CT was lower than those of the arterial phase of perfusion CT (36.1 mGy and 682.3 mGy .

118 gnificant difference between the enteric and arterial phases (P < .001) but not between the enteric a

119 red MR angiographic technique, high-quality, arterial phase, relatively motion immune angiograms can

120 10%, P < .0001) and of new severe transient arterial phase respiratory motion-related artifact (18%

121 r and aggregate rate of new severe transient arterial phase respiratory motion-related artifact (scor

122 d with significantly higher incidence of new arterial phase respiratory motion-related artifact compa

123 Frequency of greater new arterial phase respiratory motion-related artifact in ea

124 L) of gadoxetate disodium is associated with arterial phase respiratory motion-related artifact that

125 All cryolesions exhibited arterial phase rim enhancement at CT and MR imaging, and

126 Arterial phase scanning was performed with 1.25-mm secti

127 tion of arteries and of veins was greater on arterial phase scans and on venous phase scans, respecti

128 and hyperattenuating to liver on 106 of 106 arterial phase scans and were isoattenuating to liver on

129 The acquisition of arterial phase scans in addition to venous phase scans d

130 Arterial phase scans were acquired 20-40 seconds after c

131 rs identified possible or definite tumors on arterial phase studies in 47-50 patients and on venous p

132 aging with gadoxetate disodium recovers most arterial phases that would otherwise have been compromis

133 nd qualitative data were analyzed during the arterial phase, the enteric phase (which represented pea

134 During arterial phase, the liver enhanced a mean of 29% of the

135 arity relative to the adjacent cortex in the arterial phase, the presence of a capsule, homogeneity,

136 images) for the precontrast phase, the three arterial phases, the portal venous phase, and the late d

137 Imaging included an arterial phase three-dimensional (3D) fat-saturated cont

138 roximately 6 seconds per station, but a long arterial phase time window allowed bolus-chase periphera

139 igher in attenuation than the thyroid in the arterial phase, type B lesions were not higher in attenu

140 Mean CC-SC SI ratios on nonenhanced, arterial phase, venous phase, and delayed phase images w

141 arity relative to the adjacent cortex in the arterial phase was seen in only malignant lesions by bot

142 well as the number of those with "adequate" arterial phases, was compared with the chi(2) or Fisher

143 hree neoplastic lesions seen only during the arterial phase were found in eight patients with concomi

144 tients with nodules that enhanced during the arterial phase were included in the final study group, w

145 nd venous and/or late dynamic phases; >/= 4, arterial phase) were compared (McNemar test).

146 ascular liver tumors during the late hepatic arterial phase while significantly reducing patient radi

147 affected by TSM had at least one well-timed arterial phase with a mean motion score of 3 or less and

148 ak enhancement of the osteoid osteoma in the arterial phase with early partial washout, compared with